Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21038687 | 0.80 | PIK3CD (0.34) | SLC6A2SLC6A4PIK3CD | |
| SCHEMBL21038725 | 0.78 | SLC6A2 (0.55) | SLC6A2SLC6A4PIK3CD | |
| Hydrochloric Acid SCHEMBL26132023 | 0.78 | PIK3CD (0.33) | SLC6A2SLC6A4PIK3CD | |
| SCHEMBL24817708 | 0.77 | SLC6A2 (0.38) | SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29134295 | 0.75 | SLC6A2 (0.37) | SLC6A2SLC6A4 | |
| SCHEMBL22989713 | 0.74 | ALDH1A1 (0.39) | — | |
| SCHEMBL14985094 | 0.73 | DRD3 (0.43) | — | |
| SCHEMBL22200610 | 0.73 | SLC6A2 (0.37) | SLC6A2SLC6A4PIK3CD | |
| SCHEMBL25619700 | 0.72 | SLC6A2 (0.50) | SLC6A2SLC6A4 | |
| SCHEMBL23589136 | 0.72 | SLC6A2 (0.32) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | SLC6A2 4796/4885SLC6A4 4829/4885PIK3CD 1482/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | SLC6A2 4796/4885SLC6A4 4829/4885PIK3CD 1482/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | SLC6A2 4789/4885SLC6A4 4827/4885PIK3CD 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.